Nirav Niranjan Shah, MD, MS Medical College of Wisconsin 5Live #ASCO20

4:51

Key Insights on Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.

Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma Similar Videos

Similar Videos

ABOUT

Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.

The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.

CONNECT

support@bioascend.com

(888) 476-9129

980 North Michigan Avenue, Suite 1400, Chicago, IL 60611

Terms and Conditions | Privacy Policy

Nirav Niranjan Shah, MD, MS Medical College of Wisconsin 5Live #ASCO20

Diffuse Large B Cell Lymphoma Similar Videos

Future use of CD19 CAR T-cells beyond relapsed DLBCL_Jean Koff, MD, MS; #DDHO2021

Prevention of CNS Progression in Diffuse Large B-cell Lymphoma_Craig Portell, MD; #IUCLS22

Tumor Board #2: Relapsed/Refractory Diffuse Large B-Cell Lymphoma_Ranjana Advani, MD

Nirav Niranjan Shah, MD, MS Medical College of Wisconsin 5Live #ASCO20

Diffuse Large B Cell Lymphoma Similar Videos

Future use of CD19 CAR T-cells beyond relapsed DLBCL_Jean Koff, MD, MS; #DDHO2021

Prevention of CNS Progression in Diffuse Large B-cell Lymphoma_Craig Portell, MD; #IUCLS22

Tumor Board #2: Relapsed/Refractory Diffuse Large B-Cell Lymphoma_Ranjana Advani, MD

Share this video

Embed